| Literature DB >> 36046294 |
Carlos A Fernandez1,2, Joel R Narveson1, Ryan W Walters3, Neil D Patel1,2, Jessica M Veatch1,2, Kaily L Ewing1,2, Thomas J Capasso1,2, Viren P Punja1,2, Eirc J Kuncir1,2.
Abstract
INTRODUCTION: Physical stressors are common predisposing factors for takotsubo cardiomyopathy (TTC). However, the role of traumatic injuries in TTC has not been well defined. This study describes the characteristics of TTC in the broad spectrum of traumatic injuries using the information available in the National Trauma Data Bank (NTDB).Entities:
Keywords: national trauma data bank; physical stressors; stress cardiomyopathy; takotsubo cardiomyopathy; trauma
Year: 2022 PMID: 36046294 PMCID: PMC9418767 DOI: 10.7759/cureus.27411
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1(A) The number of reported TTC diagnoses by year. (B) Count of TTC diagnoses reported by race. One data point was missing from the National Trauma Data Bank. (C) Count of TTC diagnoses reported by primary insurance type.
TTC = takotsubo cardiomyopathy.
Reported comorbidities in patients diagnosed with TTC.
Data are presented as n (%). Any data that are missing out of the 95 patients are represented in the table. Comorbidity data for substance use, anticoagulant use, myocardial infarction, and mental/personality disorder were collected beginning in 2017.
TTC = takotsubo cardiomyopathy; COPD = chronic obstructive pulmonary disease.
| Missing | Statistic | |
| Smoking history | 0 | 10 (10.5) |
| Substance use disorder | 77 | 1 (5.6) |
| Steroid use | 0 | 2 (2.1) |
| Bleeding disorder | 0 | 14 (14.7) |
| Anticoagulant use | 77 | 5 (27.8) |
| Alcohol use disorder | 0 | 13 (13.7) |
| Dependent health status | 0 | 5 (5.3) |
| Hypertension | 0 | 57 (60.0) |
| Congestive heart failure | 0 | 24 (25.3) |
| Myocardial infarction | 77 | 0 (0.0) |
| Diabetes | 0 | 17 (17.9) |
| COPD | 0 | 18 (19.0) |
| Chronic kidney disease | 0 | 3 (3.2) |
| Mental/personality disorder | 77 | 2 (11.1) |
| Cerebrovascular accident | 0 | 8 (8.4) |
Figure 2(A) Count of reported mechanisms of injury type for those with TTC. (B) Count of reported ISS by categorical grouping. Six data points were missing from the NTDB in those with TTC. (C) Count of reported GCS scores by categorical grouping. Three data points were missing from the NTDB in those with TTC.
TTC = takotsubo cardiomyopathy; NTDB = National Trauma Data Bank; ISS = Injury Severity Score; GCS = Glasgow Coma Scale.
Mechanism of injury counts.
| Mechanism of injury | Count |
| Fall | 59 (62.11%) |
| Motor vehicle collision | 18 (18.95%) |
| Firearm | 3 (3.16%) |
| Cut/pierce | 3 (3.16%) |
| Other | 12 (12.61%) |
Injury characteristics by gender.
Data are presented as n (%) or median (interquartile range).
ISS = Injury Severity Score; GCS = Glasgow Coma Scale.
| Missing | Overall (N = 95) | Female (n = 64) | Male (n = 31) | P | |
| Mechanism of injury | |||||
| Blunt | 0 | 86 (90.5) | 62 (96.9) | 24 (77.4) | 0.005 |
| Penetrating | 6 (6.3) | 1 (1.6) | 5 (16.1) | ||
| Other | 3 (3.2) | 1 (1.6) | 2 (6.5) | ||
| ISS | 9 (5-16) | 9 (5-14) | 14 (9-25) | 0.007 | |
| Mild (1-8) | 5 | 27 (30.0) | 21 (35.0) | 6 (20.0) | 0.040 |
| Moderate (9-14) | 37 (41.1) | 27 (45.0) | 10 (33.3) | ||
| Severe (15-24) | 10 (11.1) | 6 (10.0) | 4 (13.3) | ||
| Profound (25+) | 16 (17.8) | 6 (10.0) | 10 (33.3) | ||
| GCS | 15 (14-15) | 15 (14-15) | 14 (13-15) | 0.002 | |
| Mild (13-15) | 3 | 74 (80.4) | 55 (90.2) | 19 (61.3) | 0.002 |
| Moderate (9-12) | 2 (2.2) | 1 (1.6) | 1 (3.2) | ||
| Severe (3-8) | 16 (17.4) | 5 (8.2) | 11 (35.5) |
Abbreviated Injury Scale body region frequency and severity by sex.
Data are presented as n (%) or median (interquartile range). Missing or absent data are presented as "-".
| Count | Severity | |||||||
| Overall (N = 95) | Female (n = 64) | Male (n = 31) | P | Overall (N = 95) | Female (n = 64) | Male (n = 31) | P | |
| Other trauma | 2 (2.1) | 1 (1.6) | 1 (3.2) | 0.549 | - | - | - | - |
| Head | 25 (26.3) | 15 (23.4) | 10 (32.3) | 0.457 | 3 (1-3) | 2 (1-3) | 3 (2-5) | 0.024 |
| Face | 9 (9.5) | 4 (6.3) | 5 (16.1) | 0.146 | 1 (1-1) | 1 (1-2) | 1 (1-1) | 1.000 |
| Neck | 2 (2.1) | 0 (0.0) | 2 (6.5) | 0.104 | - | - | - | - |
| Thorax | 11 (11.6) | 9 (14.1) | 2 (6.5) | 0.495 | 2 (1-4) | 2 (2-4) | - | - |
| Abdomen | 5 (5.3) | 2 (3.1) | 3 (9.7) | 0.326 | 2 (2-4) | - | 4 (1-4) | - |
| Spine | 10 (10.5) | 6 (9.4) | 4 (12.9) | 0.724 | 2 (2-2) | 2 (2-2) | 2 (2-3) | 0.634 |
| Upper extremity | 22 (23.2) | 13 (20.3) | 9 (29.0) | 0.437 | 2 (1-2) | 2 (2-2) | 1 (1-2) | 0.058 |
| Lower extremity | 29 (30.5) | 23 (35.9) | 6 (19.4) | 0.153 | 3 (2-3) | 3 (2-3) | 2 (1-3) | 0.134 |
In-hospital outcomes.
Any data that are missing out of the 95 patients are represented in the table. Data are presented as n (%) or estimate (95% CI).
| Missing | Overall (N = 95) | Female (n = 64) | Male (n = 31) | P | |
| All-cause mortality | |||||
| In-hospital | 1 | 11.7 (6.7-20.5) | 11.1 (5.5-22.6) | 12.9 (5.1-32.6) | 0.800 |
| ED | 4 | 0 | 0 | 0 | - |
| Hospital length of stay | 2 | 9 (8-11) | 9 (7-10) | 11 (6-19) | 0.074 |
| Intensive care unit | |||||
| No | 0 | 34 (35.8) | 27 (42.2) | 7 (22.6) | 0.071 |
| Yes | 61 (64.2) | 37 (57.8) | 24 (77.4) | ||
| Length of stay | 0 | 6 (4-10) | 4 (3-10) | 11 (5-20) | 0.076 |
| Invasive mechanical ventilation | |||||
| No | 0 | 63 (66.3) | 48 (75.0) | 15 (48.4) | 0.020 |
| Yes | 32 (33.7) | 16 (25.0) | 16 (51.6) | ||
| Duration of mechanical ventilation (days) | 0 | 8 (3-14) | 8 (3-30) | 9 (3-22) | 0.862 |
Figure 3Probability (stratified by sex) of being discharged alive from the hospital (A), being discharged alive from the ICU (B), and being extubated (C).
Shaded areas represent 95% confidence intervals.
STROBE statement: checklist of items that should be included in reports of cross-sectional studies.
STROBE = Strengthening the Reporting of Observational Studies in Epidemiology.
| Item No. | Recommendation | Section/page number | |
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | Title page, Abstract |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract | ||
| Introduction | |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Background |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Background |
| Methods | |||
| Study design | 4 | Present key elements of study design early in the paper | Methods “Study population” |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Methods “Study population” and “Study variables” |
| Participants | 6 | (a) Give the eligibility criteria and the sources and methods of selection of participants | Methods “Study population” |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Methods “Study variables” |
| Data sources/measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods “Study population” and “Study variables” |
| Bias | 9 | Describe any efforts to address potential sources of bias | Methods “Study population” |
| Study size | 10 | Explain how the study size was arrived at | “Statistical analysis” |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | “Statistical analysis” |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | “Statistical analysis” |
| (b) Describe any methods used to examine subgroups and interactions | |||
| (c) Explain how missing data were addressed | |||
| (d) If applicable, describe analytical methods taking into account of sampling strategy | |||
| (e) Describe any sensitivity analyses | |||
| Results | |||
| Participants | 13 | (a) Report numbers of individuals at each stage of the study, e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | Results “Frequency of reported TTC in the trauma population” |
| (b) Give reasons for non-participation at each stage | |||
| (c) Consider the use of a flow diagram | |||
| Descriptive data | 14 | (a) Give characteristics of study participants (e.g. demographic, clinical, and social) and information on exposures and potential confounders | Results “Basic demographics” and “Injury characteristics” |
| (b) Indicate the number of participants with missing data for each variable of interest | |||
| Outcome data | 15 | Report numbers of outcome events or summary measures | |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Results “In-hospital outcomes” |
| (b) Report category boundaries when continuous variables were categorized | |||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |||
| Other analyses | 17 | Report other analyses done, e.g. analyses of subgroups and interactions and sensitivity analyses | |
| Discussion | |||
| Key results | 18 | Summarize key results with reference to study objectives | Discussion and Conclusion |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both the direction and magnitude of any potential bias | Discussion “Limitations and strengths” |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion |
| Generalisability | 21 | Discuss the generalizability (external validity) of the study results | Discussion “Limitations and strengths” |
| Other information | |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | “Conflicts of interest and source of funding” |
Takotsubo diagnostic criteria: International and Mayo Clinic Criteria
| International Takotsubo Diagnostic Criteria | Mayo Clinic Criteria | |
| "1. Patients show transient left ventricular dysfunction (hypokinesia, akinesia, or dyskinesia) presenting as apical ballooning or midventricular, basal, or focal wall motion abnormalities. Right ventricular involvement can be present. Besides these regional wall motion patterns, transitions between all types can exist. The regional wall motion abnormality usually extends beyond a single epicardial vascular distribution; however, rare cases can exist where the regional wall motion abnormality is present in the subtended myocardial territory of a single coronary artery. | “1. Transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid segments with or without apical involvement; the regional wall motion abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger is often, but not always present. | |
| 2. An emotional, physical, or combined trigger can precede the takotsubo syndrome event, but this is not obligatory. | 2. Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture. | |
| 3. Neurologic disorders (e.g. subarachnoid hemorrhage, stroke/transient ischaemic attack, or seizures), as well as pheochromocytoma, may serve as triggers for takotsubo syndrome. | 3. New electrocardiographic abnormalities (either ST-segment elevation and/or T-wave inversion) or modest elevation in cardiac troponin. | |
| 4. New ECG abnormalities are present (ST-segment elevation, ST-segment depression, T-wave inversion, and QTc prolongation); however, rare cases exist without any ECG changes. | 4. Absence of pheochromocytoma myocarditis” | |
| 5. Levels of cardiac biomarkers (troponin and creatine kinase) are moderately elevated in most cases; significant elevation of brain natriuretic peptide is common. | ||
| 6. Significant coronary artery disease is not a contradiction in takotsubo syndrome. | ||
| 7. Patients have no evidence of infectious myocarditis. | ||
| 8. Postmenopausal women are predominantly affected." | ||
| The above text is quoted from the International Takotsubo Diagnostic Criteria from Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018;39(22):2032-46. 10.1093/eurheartj/ehy076 | The above text is quoted from Prasad A, Lerman A, and Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. American Heart Journal. 2008;155(3):408-417. 10.1016/j.ahj.2007.11.008 | |